DYN
Dyne Therapeutics, Inc. [DYN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
DYN Stock Summary
Top 10 Correlated Stocks
DYN
In the News
DYN Financial details
Company Rating
-
Market Cap
2.1B
Income
-234.25M
Revenue
3.79M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
141
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-5.59
Forward P/E
-
PEG
-2.44
P/S
-
P/B
7.54
P/C
-
P/FCF
-6.28
Quick Ratio
5.32
Current Ratio
5.32
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.91
EPS next Y
-
EPS next Q
-
EPS this Y
24.21%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
10.1%
-
-
-
-
SMA20
-4.06%
SMA50
-52.44%
SMA100
-59.95%
Inst Own
-
Inst Trans
-
ROA
-100%
ROE
-96%
ROC
-1.22%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.4-30.269
52W High
-53.3%
52W Low
+133.5%
RSI
37.86
Rel Volume
0.8
Avg Volume
1.45M
Volume
1.17M
Perf Week
3.62%
Perf Month
-41.26%
Perf Quarter
-68.87%
Perf Half Y
-70.22%
-
-
-
-
Beta
0.952
-
-
Volatility
0.09%, 1.75%
Prev Close
0.14%
Price
14.01
Change
1.16%
Company Profile
- Volume Average 1.45M
- Market Capitalization 2.1B
- Employee 141
- CEO Ms. Susanna Gatti High M.B.A.
- Headquarters Waltham,MA,US
- IPO Date 2020-09-17
-
Website
https://www.dyne-tx.com 
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
